What Hyalase Treats: Main Uses and Benefits

The primary role of Hyalase is to act as a supportive agent that helps manage symptoms and may assist with outcomes across key therapeutic contexts. The enzyme is commonly used to help with the permeation of subcutaneous injections, local anesthetics, and subcutaneous infusions, and to support the resorption of excess fluids and blood in the tissues.

Hyalase is relevant for conditions presenting with acute or disruptive episodes and symptoms related to systemic imbalance where localized fluid dispersal is needed. Common uses include managing symptoms of mild-to-moderate dehydration via subcutaneous fluid therapy, achieving broader and faster regional pain relief in procedural settings, and addressing acute manifestations like swelling, pain, or vascular compromise following dermal filler or drug extravasation events.

“It is commonly used when short-term symptomatic assistance is needed to help manage distressing localized manifestations.”

---

Quick Fact: Relief for Localized Symptom Patterns

Therapeutic Area	Symptoms/Conditions Managed	Patient Benefit
Fluid Management	Dehydration symptoms (for hypodermoclysis)	Supports comfortable fluid delivery and uptake.
Anesthesia Adjuvant	Procedural discomfort/pain	Helps achieve faster and broader area of pain relief.
Aesthetic Correction	Vascular compromise, swelling, asymmetry	Assists with resolving symptomatic obstruction to ease distress.
Extravasation	Localized swelling and pain from drug leakage	Helps reduce the overall symptom burden and potential tissue strain.

Regulatory References

1. Health Products Regulatory Authority (HPRA) of Ireland

Who Can and Cannot Use Hyalase?

Official eligibility for Hyalase (Hyaluronidase) is defined by mandatory exclusions and patient-specific restrictions found in regulatory labeling.

Contraindicated Populations: Use of Hyalase is contraindicated in patients with a documented hypersensitivity to the drug or any of its components. Furthermore, the medicine is prohibited at any site where an active infection or malignancy (cancer) is present, due to the risk of spreading localized pathology. It is also not to be used during specific anesthetic procedures, such as those for unexplained premature labor.

Conditional and Restricted Use: While generally permitted for adults and children, special care is required for specific age groups. Neonates, premature infants, and older adults require cautious administration to control fluid volume and prevent over-hydration. Caution is also advised for patients with renal impairment during fluid administration (hypodermoclysis).

Site and Route Restrictions: The medicine must not be administered via intravenous injection, injected into or around acutely inflamed tissue, or applied directly to the cornea. Hyalase is also not indicated for reducing the swelling of insect bites or stings.

Pregnancy and Lactation: Regulatory documents advise avoiding use in pregnancy unless there is no safer alternative and the need is clearly established. Use during lactation requires caution, as it is not known whether the enzyme is excreted in human breast milk.

Interactions with other medicines and products

The officially documented interaction profile for Hyaluronidase primarily relates to its physical compatibility and its documented spreading action on co-administered substances. Regulatory authorities define several interactions that fall into physical prohibitions and pharmacokinetic alterations.

---

Prohibited Admixtures and Use Restrictions

Co-administration is prohibited due to documented physical and chemical incompatibility when Hyaluronidase is mixed in a solution with medicines such as Furosemide, Phenytoin, and certain Benzodiazepines. Furthermore, official regulatory labeling strictly restricts the use of Hyaluronidase to enhance the absorption or dispersion of Dopamine or alpha agonist drugs.

---

Effects on Co-administered Medicines

Hyaluronidase acts as a spreading factor, which results in a documented pharmacokinetic effect on co-administered drugs. For instance, with Local Anesthetics, co-administration hastens the onset of effect but shortens the duration of action due to increased systemic absorption. More generally, Hyaluronidase has been reported to enhance the adverse reactions associated with other co-administered drug products.

---

Reduced Spreading Effect

Conversely, the dispersing action of Hyaluronidase may be reduced by the presence of certain other medicines. Large doses of Salicylates, Cortisone, ACTH, Estrogens, and Antihistamines may render local tissues partly resistant to the enzyme’s action, potentially requiring a larger amount of Hyaluronidase for an equivalent dispersing effect.

Enzymatic Degradation of the Extracellular Matrix

The fundamental mechanism of Hyalase involves the enzyme Hyaluronidase directly catalyzing the hydrolysis of Hyaluronic Acid (HA), a key, highly viscous component of the connective tissue's extracellular matrix (ECM). This enzymatic action immediately cleaves the HA polymers into smaller, non-viscous fragments, eliminating the physical barrier that normally restricts fluid movement.

---

Modulation of Interstitial Fluid Dynamics

The breakdown of HA leads to a rapid, localized reduction in tissue viscosity and a corresponding transient increase in tissue permeability. This physiological change transforms the local tissue into a less restrictive medium, acting as a spreading factor. The consequence is the accelerated diffusion of any co-administered fluids or substances over a wider area, enabling their faster local absorption into the vascular and lymphatic systems. The effect is temporary, as the body rapidly synthesizes new HA to restore the normal connective tissue structure.

Hyalase (Hyaluronidase) is administered as a single, acute adjuvant to facilitate the dispersion and absorption of other co-administered injected substances or subcutaneous fluids. The medicine is primarily given by subcutaneous (SC), intramuscular (IM), or local infiltration routes; Hyalase is not to be administered intravenously (IV). The pattern of use is short-term, supporting a single procedure or acute event, and is not a part of any long-term treatment schedule.

The required dose is fixed based on the procedural need. For example, to facilitate the absorption of large volumes of subcutaneous fluid (hypodermoclysis), a dose of 150 to 200 USP units is commonly used, which is injected at the start of the fluid infusion. When used to increase the dispersion of another injected drug, a typical dose is 150 units, which may be mixed directly with the solution or administered immediately prior to it.

Preparation requires that the sterile powder formulation be reconstituted immediately before use with an appropriate diluent, such as Normal Saline or Water for Injections. Administration must adhere to specific constraints, including not mixing Hyalase with certain incompatible agents like Furosemide or Phenytoin.

Dosing in specific populations includes strict volume and rate controls: in neonates and young children, the maximum rate of fluid administration must not exceed 2 mL/minute, and the total daily fluid volume must be carefully monitored to avoid over-hydration.

Research Evidence: Overview of Studies for Hyalase (Hyaluronidase)

---

Evidence for Fluid Dispersal (Hypodermoclysis)

Studies conducted during periods of increased symptom activity, such as dehydration, have explored the use of the enzyme when co-administered with fluids given under the skin. Randomized Controlled Trials (RCTs) and systematic reviews were applied in research contexts involving fluctuating or unstable symptoms of dehydration, primarily in older adults and children. These studies monitored outcomes related to systemic or functional imbalance, such as the rate at which the fluids were absorbed into the body and the total volume of fluid that could be administered at one time.

Research highlights measurements taken during the study period, with data showing patterns in the quantity of fluid administered and the time taken for absorption when the enzyme was included. However, the findings were mixed when comparing subcutaneous fluid delivery with and without the enzyme to intravenous (IV) fluid delivery examined in some studies.

---

Evidence as an Adjuvant for Local Anesthesia

Research examined the enzyme’s use in studies exploring short-term changes, specifically in procedures requiring local pain management, such as certain eye surgeries. Study types available included prospective double-blind studies and comprehensive systematic reviews, typically involving adult patients undergoing scheduled procedures.

Findings indicate patterns where the inclusion of the enzyme with the anesthetic was associated with a more rapid onset of the nerve block and a broader distribution area of the medication. Studies monitored outcomes related to activity level, such as the ability to achieve necessary muscle immobility for surgical purposes. Certainty remains low regarding the enzyme's influence on the overall duration of the anesthetic effect; reported observations were inconsistent across trials.

---

Evidence for Managing Dermal Filler Complications

For managing complications arising from hyaluronic acid (HA) dermal fillers, the evidence landscape relies heavily on professional consensus, case reports, and case series rather than large-scale RCTs. Laboratory (in vitro) studies were applied in research contexts to determine the enzyme's ability to break down the material of various HA fillers.

These clinical reports and expert statements describe the enzyme’s use in conditions associated with acute, localized manifestations following dermal filler administration. The major limitation is the lack of controlled comparative studies to establish evidence-based administration protocols, as sample sizes were modest. The evidence quality varies across studies, and the results apply only to the populations studied under the specific conditions reported.

Key Studies & References

1. Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations - JMIR Dermatology
2. Summary of Product Characteristics (Hyaluronidase 1500 IU Powder) - HPRA

Common questions about Hyalase (FAQ)

Q: How quickly does Hyalase start working after it is administered?

Regulatory information indicates that the enzyme's action of breaking down the local tissue barrier is immediate. This action facilitates the rapid dispersion of co-administered fluids or substances.

Q: How long do the effects of Hyalase typically last?

Official product information indicates the enzyme's dispersing effect is temporary (transient), meaning it is not permanent. Clinical data suggests that the normal tissue barrier structure is typically completely restored at 48 hours following injection.

Q: Does Hyalase cause pain when it is administered?

According to official product labeling, injection site pain is specifically listed as a common adverse reaction. This means pain or discomfort at the location of the injection is a frequently reported effect associated with the administration of the medicine.

Q: Are there any long-term effects associated with using Hyalase?

Long-term animal studies to assess chronic effects have not been performed. Official information describes the therapeutic purpose of the medicine as providing a temporary effect that is naturally reversed as the body restores its normal tissue structure.

Q: Is it normal to feel a slight warmth or redness where Hyalase was given?

Official prescribing information lists erythema (redness) at the injection site as a common adverse reaction. Localized redness is a known and frequently reported effect that can occur following administration.

Q: Is it possible for a side effect from Hyalase to appear much later?

While the most critical reactions, such as anaphylaxis (a severe allergic reaction), typically occur immediately, regulatory documents also list systemic reactions. These include effects like malaise, chills, and fever (pyrexia), which are classified as uncommon or rare adverse effects.

Q: Can Hyalase be used in people with certain allergies?

Hyalase is contraindicated (should not be used) in patients with a known hypersensitivity to the drug or any of its components. A skin test may be performed to check for potential hypersensitivity, which is a known contraindication for use.

Q: Are there foods or drinks to avoid while receiving Hyalase?

Official regulatory labeling for Hyalase does not list any specific restrictions or adverse interactions concerning foods or drinks. The known interactions primarily relate to co-administered medications.

Q: Does Hyalase have a specific safety classification, like prescription only?

Yes, Hyalase is classified across regulatory bodies as a prescription-only medicine. This means it is a drug that is typically administered by a trained healthcare professional.

Q: Are there any specific patient groups that are generally advised not to use Hyalase?

The medicine is prohibited for injection into sites of active infection, acute inflammation, trauma, or malignancy (cancer) because of the risk of spreading localized pathology. It is also contraindicated in patients with a history of hypersensitivity to the product.

Q: Does using Hyalase require any specific pre-procedure preparation?

The product itself requires that the sterile powder be reconstituted immediately before use with an appropriate fluid. Patient-specific preparation depends on the procedure and should be discussed with the provider.

Q: Where can I find authoritative information about Hyalase?

The most authoritative information is contained in the full official prescribing information (the drug label). This document is provided by the manufacturer and reviewed by government health authorities, and it provides complete, verified details on the drug's use and safety.

Q: Are there any known interactions between Hyalase and common over-the-counter medications?

Regulatory documents indicate that large systemic doses of certain substances may make tissue partially resistant to the enzyme's effect. This includes medicines such as Salicylates (like Aspirin) and Antihistamines.

Q: Are there different forms or strengths of Hyalase available?

Yes, the medicine is available in several formats. This includes a sterile lyophilized powder (a dried form that requires mixing) or a ready-to-use solution for injection, and it may be available in different concentrations (strengths) depending on the specific product and manufacturer.

Q: Why is Hyalase not available over the counter?

It is classified as a prescription-only injectable drug because it must be administered by a trained healthcare professional. The drug requires an accurate medical indication and monitoring for potential acute reactions during or immediately following administration.

Q: Are there known reports of Hyalase affecting fertility or pregnancy?

Official documents advise avoiding use in pregnancy unless the clinical need is clearly established and there is no safer alternative. Limited nonclinical data suggests the enzyme may not adversely affect female fertility.

Q: What type of healthcare professional typically administers Hyalase?

As Hyalase is a prescription-only injectable drug that requires specific administration routes, such as subcutaneous or intramuscular injection, it must be given by a trained healthcare professional authorized to perform such procedures.

Q: Can Hyalase be used on different parts of the body?

It is used in various sites (e.g., subcutaneous, intramuscular, intraocular) depending on the procedure. However, official warnings state it must not be applied directly to the cornea or injected into areas where there is localized infection or inflammation.

Q: What are the components of Hyalase, besides the active ingredient?

The medicine is composed of the active ingredient, Hyaluronidase, as well as inactive ingredients (also known as excipients). These other components are listed in the official regulatory description and may include substances like Sodium Chloride, Albumin Human, or Sodium Phosphate.

Q: What should be monitored after a patient receives Hyalase?

When the medicine is used for subcutaneous fluid infusion (hypodermoclysis), the patient must be closely monitored to ensure proper fluid balance. This monitoring is particularly important in infants and premature neonates to prevent the potential for over-hydration.

Q: Are there any differences in Hyalase use depending on the type of procedure?

Yes, the official labeling shows that the use of Hyalase differs by indication. The dose, the route of administration, and the overall goal of using the medicine are distinct when used for procedures such as subcutaneous fluid administration versus for the dispersion of other injected drugs.

Storage and Disposal of Hyalase (Hyaluronidase)

The storage and disposal of Hyalase must strictly follow regulatory labeling to maintain product integrity and safety. Unopened Hyalase (powder for injection) should be stored below 25^circC; however, certain solution forms approved by the FDA require refrigeration at 2^circC to 8^circC and must not be frozen.

Stability and Handling

The product must be kept in the original package container and out of the sight and reach of children. Hyalase is for single use only. Once the powder is reconstituted, the solution must be used immediately due to limited stability, and any unused contents must be immediately discarded.

Disposal Requirements

Expired or unused medicine must not be disposed of via wastewater or household waste. All disposal must comply with local regulations for pharmaceutical waste.